- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LOTUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STADA ARZNEIMITTEL | - | - | Milliarden-IPO: Stada sondiert Investoreninteresse | Der Generikahersteller aus Hessen klopft den Appetit der Investoren für einen möglichen Börsengang ab. Es könnte das größte Börsendebüt in Deutschland seit dem IPO von Porsche werden. Für den Hersteller... ► Artikel lesen | |
| IONIS PHARMACEUTICALS | 35,620 | -0,89 % | Ionis Pharmaceuticals, Inc.: Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome | Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design
Bayley-4 expressive communication selected as Phase 3 study primary endpoint
... ► Artikel lesen | |
| CSPC PHARMA | 0,581 | +1,26 % | CSPC PHARMA (01093): NEXT DAY DISCLOSURE RETURNS | ||
| ACADIA PHARMACEUTICALS | 16,720 | +0,63 % | Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | ||
| SELLAS LIFE SCIENCES | 0,850 | 0,00 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 291,30 | -0,24 % | Arrowhead Pharma und Madrigal gehen steil: Zwischen Adipositas- und Übernahmefantasie | Die Biotechnologie-Branche bietet viele spannende Storys. Einen aussichtsreichen Aktienkorb mit 14 verschiedenen Titeln bildet der Biotech Supertrends Index ab. Zuletzt sorgten im Index vor allem die... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 21,080 | +0,19 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| OPUS GENETICS | 0,978 | +11,52 % | Foundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics | The resulting company will operate under the name Opus Genetics and the Nasdaq ticker symbol (IRD)
RALEIGH, N.C., Oct. 25, 2024 /PRNewswire/ -- The RD Fund (Retinal... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,103 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| VIRACTA THERAPEUTICS | 0,184 | -9,80 % | Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | - Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets | Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 3,060 | -0,65 % | Savara Reports Third Quarter 2024 Financial Results and Provides Business Update | LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third... ► Artikel lesen | |
| GALECTIN THERAPEUTICS | 2,160 | +5,88 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update | NAVIGATE trial on track for top-line results in December 2024 NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 4,380 | +1,86 % | Biodexa Pharmaceuticals PLC: Result of General Meeting | November 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Result of General Meeting Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | SCICLONE PHARMA (06600): (1) PROPOSAL FOR THE PRIVATISATION OF SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED BY SILVER PEGASUS INVESTMENT LIMITED BY WAY ... |
Das Unternehmen LOTUS PHARMACEUTICALS INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LOTUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
